Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
|Articles|September 24, 2021
Daily Medication Pearl: Ribociclib (Kisqali) for Breast Cancer
Author(s)Saro Arakelians, PharmD
Ribociclib is an inhibitor of cyclin-dependent kinase 4 and 6 and causes tumor growth inhibition.
Advertisement
Medication Pearl of the Day: Ribociclib (Kisqali)
Ribociclib is a kinase inhibitor indicated for breast cancer.
Insight:
- Ribociclib tablets are taken orally, with or without food, in combination with an aromatase inhibitor or Fulvestrant.
- Recommended starting dose: 600 mg orally taken once daily, with or without food, for 21 consecutive days followed by 7 days off treatment.
- Dosage comes in 200 mg tablet format.
- Mechanism of action: Ribociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6 and causes tumor growth inhibition.
- Adverse events include neutropenia, nausea, infections, fatigue, diarrhea, leukopenia, vomiting, alopecia, headache, constipation, rash, and cough.
- Interactions: Avoid concomitant use of ribociclib with strong CYP3A inhibitors. Avoid concomitant use of ribociclib with strong CYP3A inducers. Avoid concomitant use of drugs known to prolong QT interval, such as anti-arrhythmic medicines.
- Manufactured by: Novartis
SOURCE:
Advertisement
Related to this article
At-home chemotherapy for HR+ breast cancer works best when pharmacists guide oral regimens, boosting adherence, safety, and affordable access.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Peptide cancer vaccines target neoantigens to boost T cells, with promising melanoma and pancreatic trials hinting at a new era in immunotherapy.
Ali A. Habib, MD, discusses how NIMBLE’s hospitalization findings complement symptom outcomes for investigational cemdisiran and highlights pharmacists’ role in vaccination tracking and infection-risk counseling.
Rather than requiring a new trial, the FDA extended evidence from carcinoma in situ to high-grade papillary-only disease, a new approach for this setting.
Pharmacists can address patient fears about fentanyl by distinguishing illicit from prescribed opioids and promoting safe, empathetic, evidence-based opioid use.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Finerenone Expands MRA Options as Pharmacists Address Underrecognized HFpEF
2
Diuretics, eGFR, and Intensive BP Lowering in CKD: What to Watch
3
Researchers Target Viral Fusion for Universal Flu, HIV Vaccines
4
Finerenone in Heart Failure: Evidence and Practice a Year Later
5